Table 1.
Characteristics of the analysed Mycobacterium tuberculosis complex isolates
| Isolates | ||
|---|---|---|
| Drugs with MIC results | ||
| Isoniazid | 898/900 (99·8%) | |
| Rifampicin | 898/900 (99·8%) | |
| Kanamycin | 895/900 (99·4%) | |
| Amikacin | 895/900 (99·4%) | |
| Capreomycin | 672/900 (74·7%) | |
| Moxifloxacin | 897/900 (99·7%) | |
| Levofloxacin | 742/900 (82·4%) | |
| Ethambutol* | 223/900 (24·8%) | |
| Pyrazinamide* | 213/900 (23·7%) | |
| Resistance profile (based on phenotypic data) | ||
| Drug susceptible | 66/900 (7·3%) | |
| Monoresistance or polyresistance | 55/900 (6·1%) | |
| Polyresistant second-line drugs† | 22/900 (2·4%) | |
| MDR | 613/900 (68·1%) | |
| XDR | 144/900 (16·0%) | |
| Lineage | ||
| Lineage one (East African—Indian) | 10/900 (1·1%) | |
| Lineage two (Beijing) | 517/900 (57·4%) | |
| Lineage four (Euro—American) | 373/900 (41·4%) | |
| Country (based on phenotypic data) | ||
| Moldova | 219/900 (24·3%) | |
| MDR | 198/613 (32·3%) | |
| XDR | 9/144 (6·3%) | |
| Georgia | 97/900 (10·8%) | |
| MDR | 77/613 (12·6%) | |
| XDR | 12/144 (8·3%) | |
| Peru | 105/900 (11·7%) | |
| MDR | 79/613 (12·9%) | |
| XDR | 2/144 (1·4%) | |
| South Africa | 282/900 (31·3%) | |
| MDR | 91/613 (14·9%) | |
| XDR | 119/144 (82·6%) | |
| Vietnam | 197/900 (21·9%) | |
| MDR | 168/613 (27·4%) | |
| XDR | 2/144 (1·4%) | |
MDR=multidrug resistant. XDR=extensively drug resistant. MIC=minimum inhibitory concentration.
*
Additional samples without MIC results and only phenotypic antimicrobial susceptibility testing results (resistant or susceptible) were available.
†
Includes isolates with resistance to either isoniazid or rifampicin, and resistance to at least one fluoroquinolone, second-line injectable drug, or to both.